Navigation Links
Vaccine Can Prevent Cervical Cancer and Precancerous Lesions

LONDON, June 28, 2007--A cervical cancer vaccine has shown 90% efficacy for prevention of cervical cancer and precancerous lesions associated with the human papillomavirus (HPV) types targeted by the vaccine, conclude authors of an Article published early Online and in the upcoming issue of The Lancet.

HPV types 16 and 18 account for 70% or more cases of cervical cancer worldwide, but there are up to 15 oncogenic HPV types which can contribute to cervical cancer.

Professor Jorma Paavonen, Department of Obstetrics and Gynaecology, University of Helsinki, Finland, and colleagues randomly assigned 9 258 women to receive the HPV 16/18 vaccine, and 9 267 women in a control group received Hepatitis A vaccine. Women who may have already been infected with HPV were included in the study, as were women who had low-grade cytological abnormalities at study entry.

With an average follow-up of 15 months, the investigators found the vaccine had 90·4% efficacy against high-grade cervical intraepithelial neoplasia (CIN 2/3, a cervical cancer precursor) associated with HPV types 16 and 18. They found also that many CIN lesions contained several oncogenic HPV types. The level of protection against persistent infections with HPV16/18 at 6 and 12 months was 80·4% and 75·9%, respectively. The study extended earlier results of cross-protection against HPV 45 and HPV 31, which cause up to 10% of cases of cervical cancer.

The authors say: "Our results show that the vaccine is effective, well-tolerated and immunogenic in a broad population of young adult women, lending support to its potential value in preventing CIN and cervical cancer."

In an accompanying Comment, Dr Jessica Kahn, Cincinnati Children’s Medical Center, University of Cincinnati College of Medicine, USA, and Dr Robert Burk, Albert Einstein College of Medicine, New York, USA, state: "Althou gh these interim efficacy data are encouraging, their interpretation has limitations. The follow-up was brief, given that cervical carcinogenesis often evolves over several decades. They also highlight increases in adverse reactions among women in the HPV vaccine group.

Finally, the Comment authors raise the issue of ensuring the vaccine is distributed in the developing world, where cervical cancer makes the largest contribution to years of life lost to cancer, concluding: "Poverty is strongly associated with high-risk HPV infection and cervical cancer. If those who live in poverty cannot access a highly effective intervention such as HPV vaccines, disparities could worsen dramatically."

Professor Jorma Paavonen, Department of Obstetrics and Gynaecology, University of Helsinki, Finland. T) +35 8400497900

Comment Dr Jessica Kahn, Cincinnati Children’s Medical Center, University of Cincinnati College of Medicine, USA. T) +1 513 636 8587

Jorma.Paavonen@hus.fi

Jessica.kahn@cchmc.org


pressoffice@lancet.com
Telephone: +44 (0)20 7424 4949/4249
'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
6. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
7. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
8. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
9. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
10. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 Australia Glaucoma Surgery ... GlobalData,s new report, "Australia Glaucoma Surgery Devices Market ... the Australia Glaucoma Surgery Devices market. The report ... (in units) and average prices (USD) within market ... also provides company shares and distribution shares data ...
(Date:12/8/2016)... KEY FINDINGS The global medical lifting sling ... for growth of the medical lifting sling market are ... high recovery cost of injuries and government initiatives to ... refers to an assistive device that helps caregiver transfer ... the lift and hold the patient. It is important ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that ... for Texas, they are expanding their presence in Dallas. One of the most exciting ... bring new jobs to the Dallas and Forth Worth market. STAT takes pride in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):